INTERVIEW WITH KENNETH PIENTA
The Biology of Prostate Cancer

INTERVIEW WITH JOAQUIN MATEO
Integrating PARP inhibitors into the Standard of Care for Prostate Cancer - Joaquin Mateo

INTERVIEW WITH SCOTT TAGAWA
Antibody-drug Conjugates for Metastatic Urothelial Carcinoma & 177Lu-PSMA-617 for Progressive mCRPC

INTERVIEW WITH JUNE CHAN
"Eat, Move, Sleep"

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie's Disease: A Population-Based Analysis.

Penile plication or partial excision with grafting has traditionally been the first-line treatment for stable Peyronie's disease (PD). Numerous injection therapies (ITs) have been introduced over the last few decades. Intralesional collagenase clostridium histolyticum (CCH) was U.S. Food and Drug Administration approved in 2013 for patients with stable disease, curvature ≥30° and ≤90°, and intact erectile function. The impact of the advent of CCH on the surgical management of PD is unknown.

We studied the effect of IT on the surgical management of PD in a population-based analysis.

The Statewide Planning and Research Cooperative System database, which provides statewide level of all-payer data on patients in the outpatient, inpatient, ambulatory, and emergency department setting in New York State was reviewed. Patients undergoing a penile prosthesis for concurrent erectile dysfunction were excluded.

Descriptive statistics and multivariable logistic regression modeling were used to assess factors influencing choice of injection therapy vs surgical therapy (penile plication or partial excision with grafting).

From 2003-2016, 547 patients with PD presented for management. Median age was 56 years and 57% were white. Over the study period, surgical management was used less often as the primary procedure with a concurrent increase in use of IT (P < .001). On multivariable modeling, patients more likely to receive IT as treatment for penile curvature were younger (odds ratio [OR]: 1.26; P = .002; CI: 1.09-1.46), of higher socioeconomic status (OR: 1.14; P = .037; CI: 1.01-1.29), presented in the post-CCH era (OR: 1.17; P = .018; CI: 1.03-1.33) and presented to a surgeon with a high volume practice (OR: 1.25; P = .007; CI: 1.07-1.48). Patients presenting in the post-CCH era were 17% significantly more likely to receive IT.

ITs like CCH are increasingly displacing surgical management as the primary treatment option of Peyronie's disease.

The Statewide Planning and Research Cooperative System database is particularly useful for this analysis because it is an all-payer database that tracks patients longitudinally across various health care settings-outpatient and inpatient.

It only includes patients in New York State limiting generalizability. The retrospective nature of the analysis makes it subject to the biases inherent in such reports. Specific disease level characteristics (eg, degree of curvature, duration of disease, and associated deformities) were not available.

Since the introduction of CCH, there has been a markedly decreasing trend in the utilization of surgery as the primary modality in the management of PD-associated penile curvature. Sukumar S, Pijush DB, Brandes S. Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie's Disease: A Population-Based Analysis. J Sex Med 2019;XX:XXX-XXX.

The journal of sexual medicine. 2019 Nov 20 [Epub ahead of print]

Shyam Sukumar, Debduth Bardhan Pijush, Steven Brandes

Department of Urology, Columbia University, New York, NY, USA. Electronic address: ., Department of Urology, Department of Biostatistics, Columbia University, New York, NY, USA., Chief, Reconstructive Urology, Given Foundation Professor of Urology, Columbia University Medical Center, New York, NY, USA.

Conference Coverage
 
Recent data from conferences worldwide
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Calendar
Upcoming educational events
January 17-19, 2020 /
ESOU 2020
February 24-27, 2020 /
2nd Nuclear Receptors Conference
February 25-29, 2020 /
SUFU 2020 Winter Meeting